In situ interleukin 5 gene expression in pediatric Crohn's disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 24, Issue 5, 1997, Pages 568-572

  Hankard, G Fromont ^a   Brousse, N ^a   Cezard J P ^b   Emilie, D ^c   Peuchmaur, M ^d  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSERM   (France)

^d NONE

Author keywords

Crohn's disease; Eosinophils; Interleukin

Indexed keywords

INTERLEUKIN 5;

ADOLESCENT; ARTICLE; CELL DIFFERENTIATION; CELL LABELING; CELL PROLIFERATION; CLINICAL ARTICLE; COLON RESECTION; CROHN DISEASE; DISEASE ACTIVITY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IN SITU HYBRIDIZATION; INFLAMMATORY INFILTRATE; LEUKOCYTE ACTIVATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RNA PROBE; SCHOOL CHILD; STATISTICAL ANALYSIS; TISSUE INJURY;

ADOLESCENT; CHILD; COLON; CROHN DISEASE; GENE EXPRESSION; HUMANS; ILEUM; IN SITU HYBRIDIZATION; INTERLEUKIN-5; INTESTINAL MUCOSA; RNA, MESSENGER;

EID: 0031011430     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199705000-00015     Document Type: Article

References (28)

1. Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665-72.
2. Dvorak AM. Ultrastructural pathology of Crohn's disease. In: Goebell H, Peskar BM, Malchow M. eds. Inflammatory bowel disease. Basic research and clinical implication. Lancaster: MTP Press, U.S.A. 1991:3-41.
3. Prin L, Capron M, Tonnel AB, Bletry O, Capron A. Heterogeneity of peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int. Arch Allergy Appl Immunol 1983; 72:336-46.
4. Yamagushi Y, Suda T, Suda J, et al. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 1988;167:43-56.
5. Lopez AF, Sanderson CJ, Gamble JR, Campbell DH, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988; 167:219-24.
6. Desreumaux P, Janin A, Colombel JF, et al. Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med 1992; 175:293-6.
7. Desreumaux P, Janin A, Dubucquoi S, et al. Synthesis of interleukin 5 by activated eosinophils in patients with eosinophilic heart diseases. Blood 1993;82:1553-60.
8. Harada N, Matsumoto M, Koyama N, et al. T cell replacing factor/interleukin 5 induces not only B cell growth and differentiation but also increased expression of interleukin 2 receptor on activated B cells. Immunol Lett 1987;15:205-15.
9. Takatsu K, Kikuchi Y, Takayashi T, et al. Interleukin 5, a T cell derived B cell differentiation factor, also induces cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1987;84:4234-8.
10. Bertolini JN, Sanderson CJ, Benson EM. Human interleukin 5 induces staphylococcal A cowan 1 strain activated human B cell to secrete IgM. Eur J Immunol 1993;23:398-402.
11. Brynskov J, Tvede N, Andersen CB, Vilien M. Increased concentrations of interleukin 1β, interleukin 2, and solubles interleukin 2 receptors in endoscopical mucosa biopsy specimens with active inflammatory bowel disease. Gut 1992;33:55-8.
12. Cappello M, Keshav S, Prince C, Jewell DP, Gordon S. Detection of mRNAs for macrophages products in inflammatory bowel disease by in situ hybridization. Gut 1992;33:1214-9.
13. Dubucquoi S, Janin A, Klein O. Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. Gut 1995;37:242-6.
14. Dubucquoi S, Desreumaux P, Janin A, et al. Interleukin 5 synthesis by eosinophils. Association with granules and immunoglobuline dependent secretion. J Exp Med 1994;179:703-8.
15. Autschbach F, Schürmann G, Qiao L, Merz H, Wallich R, Meuer SC. Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflammed gut and Crohn's disease. Virchows Arch 1995;426:51-60.
16. Morson BC, Dawson IMP. Gastrointestinal pathology. Oxford: Blackwell, 1979:551-62.
17. Emilie D, Peuchmaur M, Maillot MC, et al. Production of interleukins in human immunodeficiency virus-1 replicating lymph nodes. J Clin Invest 1990;86:148-59.
18. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:928-37.
19. Mazzucchelli L, Hauser C, Zgraggen K, et al. Expression of interleukin-8 in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol 1994;144:997-1007.
20. MacDonald T. Inflammatory bowel disease in knockout mice. Curr Biology 1994;4:261-3.
21. Rolfe FG, Hughes JM, Armour CL, Sewell WA. Inhibition of interleukin 5 gene expression by dexamethasone. Immunology 1992;77:494-9.
22. Balfour Sartor R. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994;106:533-9.
23. Radford Smith G, MacGowan I, Jewel DP. TH1 and TH2 gene cytokine in inflammatory bowel disease. Gastroenterology 1994;106:A757.
24. Chihara, J. Plumas J, Tavernier J, et al. Characterization of a receptor for interleukin 5 on human eosinophils: variable expression and induction by granulocyte/macrophage colony-stimulating factor. J Exp Med 1990;172:1347-52.
25. Wang HM, Smith KA. The interleukin 2 receptor: functional consequences of its bimolecular structure. J Exp Med 1987; 166:1055-69.
26. Mahida YR, Gallagher A, Hawkey CJ. Plasma and tissue interleukin 2 receptor levels in inflammatory bowel disease. Clin Exp Immunol 1990;82:75-80.
27. Nakanishi K, Yoshimoto T, Katoh Y, et al. Both B 151 T cell replacing factor 1 and IL5 regulate Ig secretion and interleukin 2 receptor expression on a cloned B lymphoma line. J Immunol 1988;140:1688-74.
28. Plumas J, Gruart V, Aldebert D, et al. Human eosinophils from hypereosinophilic patients spontaneously express the p55 but not the p75 IL2 receptor subunit. Eur J Immunol 1991;21:1265-70.